Takeda inks up to $500M collaboration with extra-cellular matrix biotech for NASH
With Takeda’s mass, over-the-counter sell-off nearing completion, the Japanese drugmaker is beefing up the discovery engine it wants to be the core part of the post-Shire company. On Tuesday, that meant their most recent foray into NASH — a disease that they have tried with little advanced success to develop drugs for in the past, but which remains a gold-mine for any company that can find an effective therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.